SureTrader
Interactive Brokers Advertisement
SureTrader
Home > Boards > US Listed > Medical - Drugs >

AVEO Pharmaceuticals, Inc. (AVEO)

AVEO RSS Feed
Add AVEO Price Alert      Hide Sticky   Hide Intro
Moderator: mick, 4on4off
Search This Board: 
Last Post: 6/26/2017 2:34:27 PM - Followers: 93 - Board type: Free - Posts Today: 18

AVEO ONCOLOGY, Inc. (AVEO) 


Company website: 
http://www.aveooncology.com/

AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. The company is focused on developing and commercializing its lead candidate tivozanib, a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, in North America as a treatment for Renal Cell Carcinoma and other cancers. AVEO is leveraging multiple partnerships to develop and commercialize tivozanib in non-oncologic indications worldwide and oncology indications outside of North America, as well as to progress its pipeline of novel therapeutic candidates in cancer and cachexia (wasting syndrome).


   

Product pipeline candidates include tivozanib, ficlatuzumab, AV-203 and AV-380.
 
 

AV-380 (GDF-15 Program)

In August 2015, AVEO announced an exclusive, worldwide license agreement with Novartis for the development and commercialization of AVEO’s first-in-class, potent, humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), AV-380, and related antibodies, including modified or derivative forms of any such antibody.

GDF15 is a pro-inflammatory cytokine whose elevated circulating levels have been correlated with cachexia in cachectic cancer patients and several animal models of cancer cachexia. Current evidence suggests that a pro- inflammatory state may be responsible for many of the symptoms associated with cachexia, a complex metabolic syndrome characterized by malnutrition and severe involuntary weight loss due to the loss of muscle and fat tissue, as well as the clinical manifestation of anemia, inflammation and suppression of immune functions.

Preclinical data show that inhibition of GDF15 results in a switch from catabolism to anabolism, suggesting that GDF15 inhibition with AV-380 may reverse the effects of cachexia.
Cachexia is a serious and common complication in patients with advanced cancer and other chronic diseases. It affects some five million individuals in the United States.

Tivozanib

Tivozanib, is a potent, selective, long half-life inhibitor of all three vascular endothelial growth factor (VEGF) receptors that is designed to optimize VEGF blockade while minimizing off-target toxicities.

AVEO remains encouraged by the clinical outcomes from its Phase 2 and Phase 3 studies in renal cell carcinoma and the efficacy and tolerability profile that tivozanib may offer to patients suffering from this challenging disease. In addition, promising biomarker results were observed in a Phase 2 study of tivozanib in colorectal cancer.

In August of 2014, AVEO regained all rights to tivozanib. In November 2014, AVEO entered into an option agreement with Ophthotech to investigate tivozanib for the potential treatment of non-oncologic diseases of the eye. In August 2015, AVEO entered into an exclusive license agreement with Pharmstandard OJSC for the development, manufacturing and commercialization of tivozanib in the territories of Russia, Ukraine and the Commonwealth of Independent States (CIS), for all indications excluding ocular conditions. The Company is actively pursuing partnerships in Europe to advance the development and commercialization of tivozanib in solid tumors.

AVEO is interested in collaborating with potential partners who share our vision for cancer drug development and positively impacting patients’ lives. Please contact AVEO aveobd@aveooncology.com to discuss partnership opportunities with AVEO’s development pipeline.

Ficlatuzumab

Ficlatuzumab (formerly known as AV-299) is a potent hepatocyte growth factor (HGF) inhibitory antibody that binds to the HGF ligand with high affinity and specificity to inhibit HGF/c-Met biological activities.

AVEO and Biodesix, Inc. have a worldwide agreement to develop and commercialize ficlatuzumab, with VeriStrat®, a serum protein test that is commercially available to help physicians guide treatment decisions for patients with advanced non-small cell lung cancer (NSCLC). Under the terms of the agreement, AVEO and Biodesix are conducting a proof-of-concept study of ficlatuzumab in combination with erlotinib in advanced NSCLC patients selected using BDX001, a serum protein test similar to the VeriStrat test.

An exploratory analysis from AVEO’s Phase 2 study in first-line NSCLC suggested that VeriStrat was prognostic for outcome in the epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI)-treated patients and predicted differential treatment benefit for the combination of ficlatuzumab plus TKI over TKI alone. The predictive effect was observed in both progression-free survival and overall survival endpoints
 

AV-203

AVEO scientists have demonstrated through the use of our Human Response Platform™ the importance of ErbB3 in promoting tumor growth. An increasing body of evidence also implicates the activation of ErbB3 in tumorigenesis and the development of resistance to anti-cancer agents. AV-203 is a clinical-stage ErbB3 (HER3) inhibitory antibody candidate designed to inhibit both ligand-dependent and ligand-independent ErbB3 signaling. ErbB3 is a receptor that is typically expressed in many human cancers, and AV-203 has demonstrated preclinical activity in a number of different tumor models including breast, head and neck, lung, ovarian and pancreatic cancers.

AVEO has successfully completed a Phase 1 safety study showing no dose limiting toxicities at maximum dose of 20mg/kg and CLIA (Clinical Laboratory Improvements Amendment) validation has been completed for a biomarker for potential patient selection.


 
www.aveopharma.com
Shares Outstanding   55,070,000
Institutional Ownership  31%
57 Employees
http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-irhome
 
  
One Broadway 14th Floor
Cambridge, MA 02142

Investor Relations
Phone: 617-588-1960
E-mail: ir@aveooncology.com

 
AVEO
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AVEO News: Statement of Changes in Beneficial Ownership (4) 06/23/2017 05:02:57 PM
AVEO News: Statement of Changes in Beneficial Ownership (4) 06/23/2017 05:02:31 PM
AVEO News: Statement of Changes in Beneficial Ownership (4) 06/23/2017 05:02:31 PM
AVEO News: Current Report Filing (8-k) 06/23/2017 08:37:07 AM
AVEO News: AVEO Oncology Announces Positive CHMP Opinion for Tivozanib as a Treatment of Advanced Renal Cell Carcinoma 06/23/2017 08:00:00 AM
PostSubject
#1839  Sticky Note $AVEO recent news/filings mick 11/17/15 10:42:39 AM
#2574   Many will sell at $2.00 and try to Apophis 06/26/17 02:34:27 PM
#2573   Lots of room to run after $2 micar 06/26/17 02:33:44 PM
#2572   They do still consult with Biogen Inc. Apophis 06/26/17 02:29:57 PM
#2571   Five bucks easy short term, the whole biotech Apophis 06/26/17 02:27:32 PM
#2570   There could be more news soon, another large Apophis 06/26/17 02:23:23 PM
#2569   Giddy-up for round 2 today Bullwinkle77 06/26/17 01:57:56 PM
#2568   I beg to differ with that assessment. n3m3sis 06/26/17 11:59:37 AM
#2567   Easy money Bullwinkle77 06/26/17 11:39:48 AM
#2566   Potential Elliott Wave Pattern forming on the 15m JPaso 06/26/17 11:38:52 AM
#2565   Didnt' I tell ya man! LoL n3m3sis 06/26/17 11:32:38 AM
#2564   More 1,92 europtiger 06/26/17 10:38:55 AM
#2563   Thx! 2 Break Boom europtiger 06/26/17 10:31:20 AM
#2562   Welcome to the party bro!! I never Lone Wolf 06/26/17 10:27:28 AM
#2561   Got me some 1,80's After your pm ;) europtiger 06/26/17 10:22:19 AM
#2560   Congrats to everyone who stayed the last weeks/months. dmsrz8 06/26/17 10:12:31 AM
#2559   nice move again, looking good moving forward with harry crumb 06/26/17 10:08:35 AM
#2558   K...headgies went in big Friday and volume seems Lone Wolf 06/26/17 10:04:47 AM
#2557   Looking good premarket Rodney213 06/26/17 07:44:35 AM
#2556   I like the opportunity here. Couple months 4on4off 06/25/17 10:04:15 PM
#2555   Insiders gifted with stock options. Why aren't Lone Wolf 06/25/17 09:12:16 PM
#2554   insiders starting the buying process! harry crumb 06/25/17 09:07:31 PM
#2553   hey shorty, better cover now. not saying another harry crumb 06/25/17 09:06:00 PM
#2552   Ty for the chart and explanation. Good stuff. AVEO 4on4off 06/24/17 11:00:58 PM
#2551   That's a good read. Positive momentum moving forward. 4on4off 06/24/17 12:51:28 PM
#2550   Will be watching this one as we wait 4on4off 06/24/17 12:44:18 PM
#2549   Made for a nice bounce yesterday. I like it. 4on4off 06/24/17 12:35:03 PM
#2548   * * $AVEO Video Chart 06-23-17 * * ClayTrader 06/23/17 05:09:30 PM
#2547   Let's close strong Jeff20134 06/23/17 02:35:20 PM
#2546   Just the beginning on this. Cheao now, hence Nobodys Fool 06/23/17 01:30:24 PM
#2545   Remember there are more Catalysts to come. n3m3sis 06/23/17 01:25:17 PM
#2544   adding alot more here, this could be a harry crumb 06/23/17 12:50:06 PM
#2543   Hard to say, almost 2,000,000 in short interest, Full Contact Yoga 06/23/17 10:16:31 AM
#2542   I think this going to gap up shurtha2000 06/23/17 10:15:32 AM
#2541   Get out while you can this ships bout Grizmoney22 06/23/17 10:12:20 AM
#2540   Intense Volume shurtha2000 06/23/17 10:10:36 AM
#2539   Moist shurtha2000 06/23/17 10:00:41 AM
#2538   AVEO Oncology Announces Positive CHMP Opinion for Tivozanib ProfitScout 06/23/17 09:24:45 AM
#2537   Nice news. SS to big here though Lone Wolf 06/23/17 09:00:59 AM
#2536   I think the float is actually under 70,000,000, Full Contact Yoga 06/23/17 08:24:03 AM
#2535   105M float. davidsson10 06/23/17 08:05:35 AM
#2534   Great PM, nice news... Full Contact Yoga 06/23/17 08:01:51 AM
#2533   High volume, decent news, massive PPS beat down, Full Contact Yoga 06/20/17 04:51:08 PM
#2532   AVEO Oncology Announces Pivotal Phase 3 TIVO-3 Study ProfitScout 06/20/17 08:05:40 AM
#2531   Very close to an Ichimoku cloud technical break. Sendme 06/12/17 10:31:23 PM
#2530   Should be interesting next week. tonyjh 06/12/17 12:28:29 PM
#2529   AVEO Oncology Announces Phase 1/2 TiNivo Trial of ProfitScout 06/08/17 09:15:49 AM
#2528   AVEO 85 mill held by tutes of the OptimusPrime 06/08/17 01:11:58 AM
#2527   AVEO Oncology and Biodesix Announce Results from Two ProfitScout 06/05/17 03:09:38 PM
#2526   Drops down after ASCO. Hmmm.... Woulfe 06/05/17 10:01:23 AM
#2525   This will see $1 again in due time Woulfe 06/04/17 02:59:30 PM
PostSubject